Evidence map›Paper›PMID 41471768›Full record

ArticleMolecules (Basel, Switzerland)2025

Synthesis and

Sara Janowska, Anna Makuch-Kocka, Rafał Kurczab, Oleg M Demchuk, Monika Wujec

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara JanowskaDepartment of Experimental and Clinical Pharmacology, Medical University of Lublin, 8b Jaczewskiego Street, 20-090 Lublin, Poland.
Anna Makuch-KockaDepartment of Pharmacology, Medical University of Lublin, Radziwiłłowska 11 Street, 20-080 Lublin, Poland.
Rafał KurczabDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Kraków, Poland.ORCID 0000-0002-9555-3905
Oleg M DemchukFaculty of Medicine, The John Paul II Catholic University of Lublin, 1J Konstantynów Street, 20-708 Lublin, Poland.ORCID 0000-0002-5571-1593
Monika WujecDepartment of Organic Chemistry, Medical University of Lublin, 4A Chodźki Street, 20-093 Lublin, Poland.ORCID 0000-0001-9816-1934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains the most frequently diagnosed malignant tumor among women worldwide, and the limited selectivity as well as the emerging resistance to currently used therapies highlight the need to search for new therapeutic compounds. Aromatase, a key enzyme in the estrogen biosynthesis pathway, represents a recognized molecular target in the treatment of hormone-dependent cancers. In this study, six new 1,3,4-thiadiazole derivatives containing two halogen-substituted aromatic rings were designed and synthesized as potential nonsteroidal aromatase inhibitors. The cytotoxic activity of the obtained compounds was evaluated against two breast cancer cell lines: MCF-7 (estrogen-dependent) and MDA-MB-231 (estrogen-independent). All tested compounds exhibited concentration-dependent cytotoxic activity against MCF-7 cells, with the strongest effects observed for compounds

Indexed as

Antineoplastic AgentsAromatase InhibitorsBreast NeoplasmsEstrogensThiadiazolesAromataseCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFemaleHumansMCF-7 CellsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity Relationship1,3,4-thiadiazoleAntineoplastic AgentsAromataseAromatase InhibitorsEstrogensThiadiazoles1,3,4-Thiadiazole derivativesaromatase inhibitorscytotoxicityestrogen-dependent breast cancer

Identifiers

PMID41471768
PMCPMC12736086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.